 considered as Ô¨Årst choice, in line
with the aforementioned guidelines.
As an additional alternative to single antiplatelet therapy, combination therapy with aspirin (100 mg once
daily) plus low dose rivaroxaban (2.5 mg twice daily)
should be considered for those with low bleeding risk
to prevent cardiovascular events as well as reduce extremity ischaemic events in those with CLTI, as suggested
by the GVG, ESVM, and ESC-EAS